New technology to enhance the immune system's ability to fight cancer
Official title: SIRPant Technology for anti-Cancer Immunity
Funded at Sirpant Immunotherapeutics, INC. · NIH-10919238 · Data updated 2026-11-12
This study is looking at a new way to help your immune system fight cancer by using a special treatment that boosts certain immune cells to better attack tumors, which could lead to improved outcomes for patients with advanced cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sirpant Immunotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Hummelstown, UNITED STATES) |
| Project start | September 22, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $999,999 |
| NIH project number | 5R42CA265691-03 |
| Project ID | NIH-10919238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with late-stage solid tumors, including breast and colorectal cancers.
✕Less likely to help
Patients with early-stage cancers or those whose tumors do not express CD47 may not benefit from this research.
What this research studies
This research focuses on overcoming cancer's ability to evade the immune system by targeting a specific protein called CD47. The approach involves using a proprietary reagent known as 'Phago-Act' to enhance the function of certain immune cells, specifically macrophages, which can then effectively attack and eliminate cancer cells. By improving the immune response, this research aims to activate tumor-specific T cells that can target and destroy solid tumors, particularly in advanced stages. Patients may benefit from a more effective treatment option that could lead to better outcomes in cancer therapy.
Why it matters
Potential benefit: If successful, this research could provide a novel immunotherapy that significantly improves the effectiveness of cancer treatments.
How similar studies have gone: Other research has shown promising results in enhancing immune responses against cancer using similar immunotherapy approaches, indicating potential for success.
Where this research is happening
-
Sirpant Immunotherapeutics, INC.
Hummelstown, United States Active
Researchers
- Principal investigator: Mccurley, Nathanael — Sirpant Immunotherapeutics, INC.
- Study coordinator: Mccurley, Nathanael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.